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Abstract

OPIOID ADDICTION TREATMENTS DURING PREGNANCY AND THEIR EFFECTS
ON AXONAL GROWTH AND MYELINATION IN THE DEVELOPING CENTRAL
NERVOUS SYSTEM

MANISHA MAGAR
B.A., University of Virginia, 2007
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University
Director: CARMEN SATO-BIGBEE, Ph.D
Associate Professor, Department of Biochemistry and Molecular Biology

Treatment with buprenorphine represents a promising alternative for pregnant opioid
addicts but there is a need to understand potential effects on nervous system
development. We previously showed effects of perinatal exposure to buprenorphine on
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axonal caliber and myelination in 26-day-old rat corpus callosum. These changes,
detected at the end of rapid brain myelination and accompanied by earlier
oligodendrocyte maturation, suggested interference with mechanisms coordinating
axonal growth and myelination.

To better understand buprenorphine actions and to establish whether these effects
extend to the spinal cord, we analyzed the corpus callosum and corticospinal tract at 16
days of age, just before the peak of myelination. Our results point to an important role of
the opioid system in regulating early axo-glial interactions coordinating axonal growth
and myelination. Moreover, in addition to reinforcing previous findings in the brain, we
showed for the first time that these effects are also exerted in the spinal cord.

INTRODUCTION

OPIOID ABUSE AND PREGNANCY

Opioids have been used for centuries in many different cultures for their potent
analgesic properties. However, epidemiological data clearly demonstrate that these
drugs are also highly abused. A 2008 study conducted by the Substance Abuse and
Mental Health Services Administration found that, in the United States, 4.7 million
adolescents and adults were abusing prescription opioids within the preceding month of
study (SAMHSA 2009). There has also been an increasing incidence of heroin abuse,
from 213,000 people in 2007 to 399,000 people in 2009 (SAMHSA 2010). Of greater
concern is that about 5% of pregnant women abuse illicit drugs (SAMHSA 2008). Not
only does this have the potential to harm the mother, but it could also interfere with
normal development of the unborn fetus.

Studies assessing the potential effects of opioid abuse during pregnancy suggest that in
utero exposure to these drugs may alter the developing nervous system. For instance,
the offspring of pregnant addicts show reduced head circumference, developmental
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delays, altered fine motor coordination, and risk of Sudden Infant Death Syndrome
(Rosen and Johnson 1982, Kandall et al., 1993). Some of these effects may result in
cognitive problems since longitudinal studies also show an association between in utero
opioid exposure and attention deficits (Marcus et al., 1984). However, it is difficult to
assess the accuracy and validity of these long-term studies because behavioral and
cognitive outcomes in children may be strongly affected, both in positive and negative
ways, by their family and environment.

This thesis project is a continuation of previous studies from this laboratory investigating
potential alterations of central nervous system (CNS) development induced by
buprenorphine, a synthetic opioid. As described later, use of this pharmaceutical drug is
currently under clinical trials for the treatment of pregnant opioid addicts.

OPIOIDS

Although the term opioids is often used interchangeably with opiates, the latter are in
fact defined as natural alkaloids of the opium poppy, and include morphine and codeine.
Some definitions of opiate, however, also encompass the semi-synthetic derivatives of
these natural alkaloids, such as hydrocodone and oxycodone. In general, opioids are
considered to be molecules that can bind to and exert biological functions through
opioid receptors. Heroin, methadone and buprenorphine would all be classified as
opioids.
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Endogenous Opioids

Initial investigations into the biological effects of exogenous opioids were conducted in
the hopes of identifying potential receptors involved in the action of these drugs. It
seemed unlikely, however, that vertebrates would have evolved to develop receptors for
exogenous ligands (Goldstein et al., 1968). Indeed, experiments conducted in the 1970s
revealed that the body produces endogenous opioids, and unlike morphine, which is an
alkaloid, they were classified as peptides (Terenius and Wahlström, 1975, Rosengarten
et al., 1976). So far, at least twenty different endogenous opioid peptides have been
identified as members of three main groups represented by endorphins, enkephalins,
and dynorphins (Li et al., 1976, Waterfield et al., 1976, Kuhar, 1978, Goldstein et al.,
1979).

Opioid Receptors

These and subsequent studies led to the classification of the G protein-coupled μ, δ,
and κ-opioid receptors, to which endogenous opioids differentially bind (Lord et al.,
1977). Later studies also identified the nociceptin receptor (NOP). While involved in pain
management, this receptor does not bind endogenous opioids but instead recognizes
the endogenous peptide, nociceptin/orphanin FQ (Meunier et al., 1995, Reinscheid et
al., 1995). While most cells express opioid receptors, these molecules are highly
enriched in the peripheral and central nervous systems (PNS and CNS, respectively).
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OPIOID MAINTENANCE THERAPY

Substitution treatments for opioid addiction include methadone, a synthetic opioid
developed in Germany in 1937. Although structurally different (Figure 1), it functions like
heroin as a μ-opioid receptor agonist, making it generally successful in methadone
maintenance treatment programs (Sim, 1973). Its potent analgesic properties have also
deemed it effective in pain management. Moreover, it is currently the standard FDAapproved drug for the treatment of opioid addiction in pregnant mothers. However,
methadone is known to cause an increased risk of neonatal abstinence syndrome
(NAS), which is characterized by, among other things, dysfunction of the
gastrointestinal, respiratory, and autonomic nervous systems (Finnegan, 1992).

New opioid addiction treatments employ buprenorphine, a synthetic derivative of
thebaine that functions as a μ-opioid receptor partial agonist (Martin, 1979) and κreceptor antagonist (Leander, 1987). It has also been shown to exert both agonistic and
antagonistic effects on the δ-opioid receptor (Sadee et al., 1982, Huang et al., 2001).
This drug has been successfully used in opioid addiction treatment (Mattick et al.,
2008), particularly because the withdrawal effects are less severe than other
treatments, such as methadone (Jasinski et al., 1978, Martin, 1979, Mello and
Mendelson, 1980). However, the effects of this drug in utero are widely unknown, and
thus, it is not yet FDA-approved for use during pregnancy. Given that buprenorphine
has been shown to decrease the severity of NAS in neonates (Jones et al., 2010), the
prospect of using this drug as a first-line medication for pregnant addicts is promising.
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As already noted, the in utero effects of buprenorphine on the fetus must be further
studied before it can be safely considered as a substitution therapy for opioid addiction
during pregnancy. Studies from our collaborator, Dr. Susan Robinson, have shown that
rat pups, perinatally exposed to a supra-therapeutic dose of buprenorphine, exhibit a
reduction in the levels of acetylcholine (Robinson 2002b) and neurotrophic factor nerve
growth factor (Wu et al. 2001) in rat striatum.

More recently, studies from our laboratory have shown that perinatal exposure to
buprenorphine affects myelination and oligodendrocyte maturation in the developing rat
brain (Sanchez et al, 2008, Eschenroeder et al., Manuscript under review). Before
detailing these later results, the following sections will focus on the biology of glial cells
and myelination.
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Figure 1: The chemical structures of heroin, methadone, and buprenorphine.
These opioids are clearly structurally different. Still, methadone selectively binds the
mu-opioid receptor, like heroin. Buprenorphine, however, acts as a mu-opioid receptor
partial agonist and a kappa-opioid receptor antagonist.
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GLIAL CELLS

Neuroglia were first described as “nervenkitt”, or nerve glue, by the German pathologist
Rudolf Virchow. They differ from neurons by their inability to conduct action potentials,
and have generally been thought of as supporting cells in the brain. In recent decades,
however, it has become increasingly clear that these cells have functions that extend far
beyond the simple maintenance and protection of neurons.

In the CNS, there are five types of glia: microglia, oligodendrocytes, astrocytes,
ependymal cells, and radial glia. Microglia are of mesodermal origin, whereas the other
glial types, the macroglia, are of ectodermal origin.

Microglia normally exist in a resting state (Penfield, 1925), but under pathological
conditions, they are transformed into highly phagocytic cells that play a crucial role in
inflammatory reactions (del Río-Hortega and Jiménez de Asúa, 1921, Penfield, 1925).
Astrocytes play a wide variety of functions including the recycling of neurotransmitters
(Rothstein et al., 1996, Figley and Stroman, 2011), regulation of pH and ionic
concentration (Sofroniew and Vinters, 2010, Allaman et al., 2011), modulation of
synaptic plasticity (Christopherson et al., 2005, Barker and Ullian, 2010), and
participation in the induction and function of the blood-brain barrier (Abbott 2002,
Hawkins and Davis, 2005, Abbott et al., 2006). Ependymal cells are ciliated cells that
line the brain ventricles and the central canal of the spinal cord (del Bigio 1995) and aid
in the production of cerebrospinal fluid (CSF) (Keep and Jones, 1990). The role of radial
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glia is primarily developmental, playing a pivotal role in neuronal migration (Rakic, 1972,
Edmondson and Hatten, 1987) and, as recently discovered, in neurogenesis (Noctor et
al., 2001) and astrocyte generation (Mission et al., 1991). Since oligodendrocytes are
pertinent to the topic of this thesis, their functions will be discussed in the following
section.

Oligodendrocytes

The most known role of this CNS cell type parallels that of the PNS Schwann cell; it
provides insulation to axons in order to increase the conduction velocity of neuronal
signals via the production of myelin. Unlike a Schwann cell, which provides myelin for
one internode of one axon, a single oligodendrocyte may myelinate up to 50 axons
(Hildebrand et al., 1993).

Recently, it has become clear that oligodendrocytes may have other important functions
besides myelination. Not only are they thought to signal back and forth with neurons,
but it has also been suggested that they have an important role in neuronal
development, survival, and the integration of neuronal networks. For instance, recent
studies have demonstrated that oligodendrocytes are required for the normal
development of the cerebellar cortex and the neuronal networks within (Mathis et al.,
2003, Collin L et al., 2004, Doretto et al., 2011). In support of a role in survival, it has
been found that the loss of gap junction connexins in oligodendrocytes leads to early
mortality (Magnotti et al., 2011). Moreover, oligodendrocytes can refine neuronal
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networks through the action of oligodendrocyte myelin glycoprotein (OMgp), which
inhibits neurite outgrowth at the nodes of Ranvier (Huang et al., 2005).

The Development of Oligodendrocytes

Since the process of myelination is so heavily dependent on oligodendrocyte
precursors, before we discuss myelin, we must first understand the progressive stages
of oligodendrocyte development (Figure 2). Oligodendrocyte precursor cells (OPCs)
arise from neuroepithelial cells of the subventricular region of the brain and spinal cord
and ultimately differentiate into oligodendrocytes (Rowitch 2004). These cells are
mitotically active, migratory, and immunopositive for NG2, which is a chondroitin sulfate
proteoglycan (Nishiyama et al., 1996, Baumann and Pham-Dinh, 2001). They can be
characterized as having only one or two processes.

Mediated by a signal from thyroid hormone, oligodendrocyte progenitors differentiate
into pre-oligodendrocytes, which are non-migratory and post-mitotic (Almazan et al.,
1985). Unlike their OPC predecessors, pre-oligodendrocytes are immunopositive for the
O4 antibody against sulfatides (Bansal et al., 1989), as well as for the cytoskeletal
protein cyclic nucleotide phosphohydrolase (CNP). Even as the cells mature into
oligodendrocytes, they will continue to express these molecules (Baumann and PhamDinh, 2001). Morphologically, pre-oligodendrocytes have a few more processes than
OPCs. The complexity of processes increases as the cells mature, and once fully
differentiated, the cells can be characterized by their expression of the myelin proteins,
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MBP (myelin basic protein) and PLP (proteolipid protein) (Baumann and Pham-Dinh,
2001).

Opioid Receptors in Oligodendrocyte Differentiation

In vitro studies of immature oligodendrocytes have demonstrated that activation of the
μ-opioid receptor enhances the rate of DNA synthesis, and inhibition of the κ-opioid
receptor increases the size of membrane extensions, which will eventually wrap axons
in the myelination process (Knapp et al., 1998). Based on these findings, it has been
suggested that this endogenous opioid system may regulate oligodendrocyte
differentiation. While studies have demonstrated that the synthesis of endogenous
opioids occurs in a developmentally-regulated manner (Kanpp et al., 2001),
experiments investigating the temporal expression of opioid receptors have proved to
be generally inconclusive. Some studies suggest that the expression of μ-opioid
receptors precedes that of κ- and δ-opioid receptors (Knapp et al., 1998, Tryoen-Toth
et al., 2000), while others suggest that these three receptors are expressed throughout
oligodendrocyte development (Hauser et al., 2009).
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Figure 2: The Development of Oligodendrocytes. This image depicts the progression
of a precursor cells as it differentiates into a mature oligodendrocytes. The basic
morphology and markers for each stage of development are depicted, as well as the
ability to mitotically divide. Modified from Arenander and de Vellis (1995).
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THE MYELIN MEMBRANE

Completely mature oligodendrocytes are capable of producing myelin, a multilamellar
structure essential to the CNS. As described in detail in the following sections, in the
CNS, myelin is formed from an outgrowth of the oligodendrocyte membrane that wraps
around axons, providing electrical insulation. Its lipid-rich and water-poor composition is
ideal for this function and serves to increase conduction velocity of electrical signals. In
addition to insulating axons, myelin has been shown to have other significant functions,
including the maintenance of axons and determination of axonal caliber (Yin et al.,
1998, Brady et al., 1999).

The Structure of Myelin

Myelin is organized such that it forms segments, or internodes, of 150-200 microns
along the length of the axon separated by unmyelinated points, termed nodes of
Ranvier (Butt and Ransom, 1989). Sodium channels cluster at these nodes, and are the
basis of saltatory conduction, which will be explained in a later section.

Electron microscopy (EM) images of axons show alternating concentric electron dense
and light layers. The dark line is termed the major dense line, and is formed when
cytoplasmic surfaces of the oligodendrocyte processes come together, which is thought
to be via the action of MBP (Baumann and Pham-Dinh, 2001). The lighter line is termed
the minor dense line, or the intraperiod line, and is formed by the apposition of the two

14

outer leaflets, and is thought to be via the action of proteolipid protein (PLP) , a myelin
protein (Baumann and Pham-Dinh, 2001). In cross section, EM images of axons
surrounded by compacted myelin will show the inner extension of the oligodendrocyte
process, forming the periaxonal layer of myelin. The end of this innermost extension is
sometimes referred to as the inner leaflet, or the “tongue” (Figure 3) because it contains
relatively more cytoplasm than the rest of the compact myelin membrane, (Ross et al.,
1962, Seggie and Berry, 1972), from which the cytoplasm has been mostly extruded
(Sturrock and McRae, 1980). The periaxonal layer is an interesting area to study since it
directly overlies the axon and is a likely area of axo-glial interactions and signaling.

The Role of Myelin in Action Potential Conduction

In unmyelinated axons, axonal caliber is the major determinant of conduction velocity. In
these unmyelinated fibers, action potentials are propagated via local circuits (Hodgkin,
1937a, Hodgkin 1937b, Hodgkin, 1939). Depolarization of an axon is initiated with an
influx of positively-charged sodium ions via voltage-gated sodium channels, leaving a
relative negative charge in the local extracellular environment. This internal positive
charge is sufficient to cause the adjacent intracellular environment to reach threshold
potential, causing an influx of positive charge here also. Since there are ion channels
distributed along the axolemma, this process will continue, and the action potential will
travel down the axon (Firgure 4a).
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A driving evolutionary force to conserve space yet maintain high conduction velocity is
the development of myelin. Unlike its unmyelinated counterpart, myelinated fibers do
not have sodium channels along the entire length of the axon. Rather, they are
restricted to the nodes of Ranvier, the only points along the axon with axonal membrane
exposed to the extracellular space. In this way, when there is a depolarization at one
node, the high membrane resistance of the internode causes the impulse to “jump” to
the next node for a subsequent depolarization (Lillie, 1925, Huxley and Stämpfli, 1949).
This process, known as saltatory conduction, allows for a faster propagation of the
action potential without an exorbitantly large axonal caliber (Figure 4b).

Myelin Membrane Components and Their Role in Myelination

The dry mass of myelin membrane is 70% lipid and 30% protein. This differs from most
biological membranes in that myelin has a lesser proportion of protein to lipid. It is this
fundamental property that gives myelin its hydrophobicity, and along with the existence
of multiple lamellae, its functional insulation.

The relative proportions of membrane lipids in myelin are unique. Myelin membrane is
unusually enriched in cerebroside or galactosylceramide. These galactolipids constitute
about 30% of the total myelin lipids and they are partially present in their sulfated form,
sulfatides (Norton and Cammer, 1984). It was originally thought that these lipids were
involved in myelin formation, but knockout studies suggested otherwise. The deficient
animals still form relatively normal myelin, but with age, exhibit hindlimb paralysis and
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deficits in myelin integrity. This suggested a role in insulation and myelin stability
(Coetzee et al., 1996). Other major lipids in myelin are cholesterol, ethanolamine
phosphatides, and lecithin.

Myelin proteins constitute a fifth of the dry mass of myelin, and several of these proteins
are specific to myelin. Proteolipid protein (PLP) and myelin basic protein (MBP) together
make up 80% of myelin proteins, making them the most abundant (Morell et al., 1973).

Alternative splicing of a single gene yields PLP in two isoforms: 20 kDa and 25 kDa.
PLP has long been implemented in the process of myelin compaction, but PLP knockout
studies showed that this protein is not required for normal myelin formation. It is
important to note, however, that the intraperiod line and motor skills of these animals
are affected (Klugmann et al., 1997), suggesting a role in the maintenance of compact
myelin.

Several forms of MBP also exist and also result from the alternative splicing of a single
gene (de Ferra et al., 1985). Together, they make up 30% of myelin proteins (Boggs,
2006). The major isoforms, 14kD and 18.5 kD, are localized to the oligodendrocyte
membrane, whereas the 17 kD and 21.5 kD isoforms are found in the nucleus,
suggesting a role in the regulation of myelination (Pedraza, 1997). MBP has also been
shown to have an important role in myelin compaction. Transgenic shiverer mice, which
are MBP-deficient, exhibit thinner myelin and lack the major dense line in the CNS
(Privat et al., 1979, Rosenbluth, 1980). Reintroducing the wild-type MBP gene to
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shiverer mice restores the ability to form compact myelin and major dense lines,
confirming MBPʼs role in myelin compaction (Readhead et al. 1987).

The extracellular domain of myelin-associated glycoprotein (MAG) is localized to the
periaxonal space, which is between the first myelin wrap and the axolemma. As
suggested by its location, it is thought that MAG facilitates signaling between myelin and
the axonal membrane (Quarles, 2007). Although there is not much evidence to suggest
that MAG has a role in myelin formation, it has been implicated in the stabilization of
myelin and regulation of axonal caliber (Li et al., 1994, Montag et al., 1994, Yin et al.,
1998).

Myelination is a complex process that is extensively studied but still poorly understood.
Certainly, the timing of myelination in the CNS appears to be somewhat dependent on
oligodendrocytes and their precursors in varying stages of development (Yang et al.,
2011). As described above, studies strongly indicate several myelin components are
involved in myelin formation and maintenance. There are additional molecules
expressed by oligodendrocytes that have been implicated in the production of myelin,
and one such example is the cell adhesion molecule and receptor, α6β1 integrin. This
molecule can be activated by “outside-in” signals such as extracellular matrix ligands, or
“inside-out” signals, such as R-Ras. Increasing either of these signals results in
increased myelin formation (Olsen and Ffrench-Constant, 2005). Despite the extensive
research conducted to understand how myelin is deposited around axons, much of the
process is still unknown.
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In this regard, previous studies from our laboratory revealed that exposure to
buprenorphine during development affects rat brain myelination. Perinatal exposure to
therapeutic levels of this drug induced accelerated and increased expression of all
splicing isoforms of MBP, a protein that, as indicated above, is essential for myelin
compaction and is also a marker of mature oligodendrocytes. In contrast, supratherapeutic drug doses delayed MBP expression and also resulted in reduced number
of myelinated axons in the corpus callosum (Sanchez et al., 2008).

Interestingly, EM images from 26 day old animals showed that regardless of the dose,
perinatal exposure to buprenorphine results in axons with an increased caliber and a
disproportionately thinner myelin sheath. Further experiments demonstrated that the
buprenorphine-exposed animals also exhibited higher levels of MAG and its interaction
with the Src-family tyrosine kinase Fyn (Sanchez et al., 2008).

These findings suggested that exposure to buprenorphine during brain development
interferes with mechanisms that coordinate axonal radial growth and myelination,
raising the possibility that endogenous opioid signaling plays a role in their regulation.
The following section discusses the mechanisms known to regulate axonal caliber,
including the potential role of myelination.
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Figure 3: An axon surrounded by compacted myelin and the remaining “tongue”
of cytoplasm. This image was taken from the corpus callosum of a 16 day-old
buprenorphine-treated female rat. The myelin membrane is already mostly compacted,
but the periaxonal pocket of cytoplasm remains.
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Figure 4: The propagation of action potentials in unmyelinated and myelinated
axons. The first image shows how an action potential is propogated via local circuits in
an unmyelinated axon (a). The second image shows how the insulating capacity of
myelin membrane forces signals to jump from node to node, thus increasing conduction
velocity (b). Modified from Basic Neurochemistry, edited by Siegel, Albers, Brady and
Price, Elsevier, 2005.
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DETERMINATION OF AXONAL CALIBER

It has long been thought that glial development and axonal growth are “co-regulated” by
bidirectional axo-glial interaction and signaling. In support of this possibility, maturing
myelinating axons experience a remarkable increase in axonal radial growth.
Importantly, this dramatic growth is restricted to the myelinated areas of the axons and
thus, its induction has been attributed to the myelinating glial cells (Sanchez et al.,
1996).

It is important to note that most studies investigating interactions between axons and
myelin-producing cells have been conducted in the PNS, mainly because it is
anatomically easier to access. Thus, many developments in scientific thought regarding
these interactions come from examining Schwann cells and the sciatic nerve, which is
the longest and widest nerve in the body, beginning in the lower back and extending
down to the lower leg. One such pivotal study was conducted with a trembler
hypomyelinating mutant mouse, which has a point mutation in the gene for peripheral
myelin protein 22 (PMP22), and is used as a model for Charcot-Marie-Tooth Disease,
the most common neuropathy of the PNS. The trembler sciatic nerve exhibited
decreased axonal caliber as compared with normal animals (Aguayo et al., 1979).
However, nerve transplantation from wild-type mice suggested that this reduced axonal
caliber was due to an absence of compact myelin produced by the Schwann cell, and
not an abnormality of the actual neuron (Aguayo et al., 1979).
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To investigate the CNS, studies were conducted with Shiverer mice, which are mutants
with a deletion of the MBP gene. Results from these studies suggested that formation of
myelin by oligodendrocytes is essential to the normal maturation of the cytoskeleton and
thus, the radial growth of large caliber myelinated axons (Brady et al., 1999).

How myelinating cells could affect axonal caliber is not fully understood, but under
normal developmental conditions, this increase in caliber is known to be accompanied
by local accumulation and phosphorylation of neurofilaments, the intermediate filament
proteins of the neuronal cytoskeleton (Friede and Samorajski, 1970, Cleveland et al.,
1991, de Waegh et al., 1992, Hsieh et al., 1994, Sanchez et al., 1996).

Neurofilaments are composed of three different subunits, high- (NFH, 180-200 kDa),
medium- (NFM, 130-170 kDa) and low-molecular weight (NFL, 60-70 kDa) (Shaw et al.,
1982, Lee et al., 1986), which interact through their amino-terminal region via alphahelical coils to form the core of the filament (Geisler et al., 1983). In addition, the NFM
and NFH subunits have long carboxy-terminal regions that generate sidearms
protruding from the NFʼs core. Numerous phosphorylation sites on these sidearms are
responsible for the charge-dependent repulsion that occurs between adjacent NFs and
is thought to be a major determinant of axonal radial growth (Hirokawa et al., 1984,
Nakagawa et al., 1995).

As indicated above, altered axonal growth and myelin thickness induced by
buprenorphine were detected in the corpus callosum at 26 days postnatal (P26), which
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is an age at which rat brain myelination slows down towards basal adult levels.
However, it is possible that buprenorphine is (1) exerting its effects on white matter tract
morphology at an earlier stage of development and (2) that these effects are not limited
to the brain and may also be detected in the spinal cord. Before we can attempt to
further our understanding of the timeline and scope of these potential effects, we must
first discuss the development and myelination of the CNS.

CORPUS CALLOSUM AND SPINAL CORD DEVELOPMENT

The corpus callosum is a commissure of axons that not only connects the two
hemispheres of the brain, but also the cortex with the subcortex (Georgy et al. 1993). It
is comprised of the genu anteriorly and the splenium posteriorly, connected by the body.
Connected to the genu and lying inferior to the body is the rostrum. The corpus
callosum is a common area of study for the analysis of CNS axons because (1) it is one
of the largest concentrations of white matter in the CNS and (2) it is composed of
parallel axons. Thus, a mid-sagittal section of the brain yields cross-sections of axons
that can be analyzed for diameter and myelin thickness.

Development of the corpus callosum is such that only rostral fibers have crossed the
midline by the time of birth (Seggie and Berry, 1972). Early myelination studies of the
corpus callosum have demonstrated that it is not until between P10-13 that there are
overt signs of myelination (Seggie and Berry, 1972). In actuality, different areas of the
brain may begin myelination at different times, but studies with total brain homogenates
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have shown that on average, it begins at around the aforementioned P10 (Siegel et al.,
2005). This corresponds to a time in oligodendrocyte differentiation when the cells are
capable of myelinating axons. The peak of myelination is at around P20, when myelin
accumulation occurs at its maximal rate of 3.5 mg/day (Siegel et al., 2005), and the end
of rapid myelination occurs in one month-old animals.

The corticospinal tract carries motor information from higher brain centers to
motoneurons of the body. It begins with pyramidal neurons residing in layer V of
cerebral cortex, travels ipsilaterally via the medullary pyramid, and down the
contralateral spinal cord. This tract is constituted by several components, including a
dorsal, intermediate, lateral, and ventral component (Goodman et al., 1966, Schreyer
and Jones 1982).

Compared to other tracts in the rodent spinal cord, the corticospinal tract is latedeveloping. Although extension of the tract from the cerebrum begins in embryological
stages, it does not reach the upper cervical spinal cord until birth (Gribnau et al., 1986),
and the tract is not fully developed until about P14 (Reh and Kalil, 1981). Myelination,
however, begins just before the tract has completed its extension at around P10. In a
one month-old rat, almost half of the axons are already myelinated, and in a three
month-old rat, one third of the axons remains unmyelinated (Gorgels et al., 1989,
Gorgels et al., 1990).
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Figure 5: The Rate of Accumulation of Myelin in the Brain. Myelination can be
detected as early as P1, but on average, myelination begins at around P10. The rate of
myelin accumulation peaks at P20, at a rate of 3.5 mg/day (Siegel et al., 2005). This
period of rapid myelination ends at about one month of age, at which point the rate of
myelination slows towards basal adult levels.
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The purpose of this thesis was to expand our current limited knowledge of the effects of
buprenorphine on CNS development and in particular, to better understand the timeline
of buprenorphine actions on axo-glial interactions. As described earlier, previous studies
in our laboratory have investigated the effects of buprenorphine on 26 day-old animals,
which corresponds to the end of rapid myelination in rodents.

To build on our previous studies and establish whether the effects of this drug on axonal
growth and caliber begin earlier in development, we have now used EM to analyze the
corpus callosum of 16 day-old animals, which corresponds to a time point midway
between the beginning and peak of rapid myelination. Moreover, at this age, even
though much of the spinal cord is already myelinated, the corticospinal tract is still in the
early stages of myelination. We analyzed this tract to determine whether the effects of
buprenorphine extend to the spinal cord.

Results from the present studies support the involvement of axo-glial interactions in the
regulation of axonal caliber at an earlier stage of development. Moreover, in addition to
reinforcing previous findings from our laboratory that suggest a buprenorphine-induced
acceleration of oligodendrocyte differentiation in the brain, we now propose that this
also occurs in the spinal cord.
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MATERIALS AND METHODS

MATERIALS

The timed-pregnant Sprague-Dawley rats were provided by Harlan Laboratories
(Frederick, MD). Model 2ML4 Alzet osmotic minipumps were obtained from Durect
(Cupertino, CA). Buprenorphine was provided by Sigma-Aldrich (St. Louis, MO). The
Jeol JEM-1230 transmission electron microscope (TEM) equipped with a Gatan
UltraScan 4000SP 4K x 4K CCD camera are maintained by the VCU Department of
Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from
NIH-NINDS Center core grant (5P30NS047463-02).

BUPRENORPHINE TREATMENT

This study was conducted in accordance with the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal Resources, National Academy Press,
1996) and under protocols approved by the Animal Care and Use Committee of Virginia
Commonwealth University. Female rats were implanted subcutaneously with 28-day
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osmotic minipumps on day 7 of gestation, as previously reported (Sanchez et al., 2008).
Control animals were implanted with pumps containing sterile water while the
experimental group was implanted with pumps delivering 0.3 mg/kg/day of
buprenorphine in sterile water. In this way, rat embryos began exposure to the drug just
before the beginning of rapid myelination in the brain. Postnatally, the pups continued
drug exposure, since buprenorphine passes into the breast milk (Kunko et al., 1996). It
is important that the pups were exposed to the drug after birth because rats are born at
a stage of development comparable to the end of the second trimester in human
pregnancy. Therefore, the administration of buprenorphine postnatally signifies a
continued exposure to the drug at a critical time in CNS development when
oligodendrocytes in the brain are rapidly myelinating. The drug dosage was chosen
because it is equivalent to the treatment dose for humans.

TISSUE PREPARATION

Rats were sacrificed at P16, corresponding to a time point between the beginning and
peak of myelination in the CNS. In total, eight animals were prepared, two each of
control males, buprenorphine-treated males, control females, and buprenorphinetreated females. Animals were anesthetized by intraperitoneal injection with 1 cc of
2.5% Avertin (tribromoethanol and tertiary amyl alcohol), and when unresponsive to foot
squeeze, perfused transcardially with phosphate buffer saline (PBS) containing 4%
paraformaldehyde and 2% glutaraldehyde, in the same buffer, as described previously
(Dupree et al., 2004). The brains and spinal cords were removed and fixed overnight in
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the same fixative. Regions of the corpus callosum approximately mid-way between the
genu and splenium were analyzed as was the dorsal corticospinal tract in the cervical
spinal cord.

ELECTRON MICROSCOPY

Cervical spinal cords and brain regions containing the middle portion of the corpus
callosum were dissected, postfixed with 1% osmium tetroxide in 100 mM sodium
cacodylate buffer, pH 7.3, and plastic embedded. Ultrathin sections were collected on
copper grids and stained with lead citrate and uranyl acetate. They were examined
using a Jeol JEM-1230 transmission electron microscope equipped with a Gatan
UltraScan 4000SP 4K x 4K CCD camera. Representative fields from each treatment
group were photographed at 5,000X magnification, with a minimum of four 17x17
micron fields per sample. To facilitate identifying the areas of interest in the electron
microscopy field, one micron thick cross-sections of the regions of interest were
mounted onto glass slides and stained with toluidine blue.

IMAGE ANALYSIS

Corpus Callosum

Two animals were processed, however axons in the corpus callosum of only one animal
from each treatment group were analyzed for diameter, number of myelin wraps and
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total myelin thickness. The diameter of each axon was determined by calculating the
average of the maximal and minimal diameters. To establish the number of myelin
wraps, we printed and manually counted the number of oligodendroglial membranes
surrounding the axon, and for partially compacted or compacted axons, this was
determined by counting the number of major dense lines. From each treatment group,
between 65-200 axons that exhibited at least one wrap of myelin membrane were
analyzed for axonal diameter and number of myelin wraps, and for the basis of
comparison, a sample of unmyelinated axons was also analyzed for axonal diameter. Of
the axons analyzed for diameter and number of myelin wraps, only those that exhibited
compacted myelin were analyzed for myelin thickness. Myelin thickness was examined
in relation to axonal diameter, as represented by the g-ratio, which was calculated by
dividing the diameter of the axon by the diameter of the axon with myelin membrane
(Figure 6) (Rushton, 1951).

Corticospinal Tract

Axons in the corticospinal tract (one male per group, two females per group) were
analyzed for overall degree of myelin compaction. Only axons that exhibited at least one
wrap of myelin membrane were analyzed for each of these parameters. Since
myelination in the spinal cord precedes that of the corpus callosum, there were many
more axons in the corticospinal tract that were surrounded by myelin membrane and
could thus be analyzed for degree of myelin compaction. Between 280-374 axons were
analyzed for each treatment group. Axons were assigned to one of the following groups:
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(1) one wrap of myelin membrane, (2) multiple but uncompacted wraps of myelin
membrane, (3) partially compacted membranes, or (4) fully compacted myelin
membranes. These categories are further defined in the “Results” section. The
percentage of axons within each of these groups was calculated and compared
between each treatment group.

STATISTICAL ANALYSIS

Statistical analysis was performed by one-way analysis of variance using the GraphPad
Prism program. When the p-values were less than 0.05, the differences between groups
were considered statistically significant.
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Figure 6: Measurements to determine the g-ratio. The g-ratio is the diameter of the
axon (A) divided by the diameter of the axon with myelin (B). A larger g-ratio represents
a thinner myelin sheath relative to the diameter of the axon, and a smaller g-ratio
represents a thicker myelin sheath relative to the diameter of the axon.
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RESULTS

ANALYSIS OF BUPRENORPHINE EFFECTS ON AXONAL RADIAL GROWTH AND
MYELIN FORMATION AT EARLY STAGES OF CORPUS CALLOSUM MYELINATION

As described previously, earlier studies from our laboratory conducted on 26 day-old
animals have found that perinatal exposure to a supra-therapeutic dose of
buprenorphine reduces the number of myelinated axons in the corpus callosum
although no differences in this regard were detected in the animals exposed to a
therapeutic dose of the drug. However, regardless of the buprenorphine dose,
myelinated axons in both experimental groups exhibited increased caliber and a
disproportionately thinner myelin sheath (Sanchez et al., 2008).

At P26, the rate of myelination in the rat brain has already begun decrease,
approaching basal adult levels. This raised the question of whether those changes in
axon morphology and myelination induced by buprenorphine could be seen earlier in
development. Answering this question should help to further understand buprenorphine
effects and provide important clues on the role of opioids in regulating myelination and
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axo-glial interactions. We therefore decided to analyze the corpus callosum of animals
at 16 days of age, a developmental time point that immediately precedes the peak of
myelination and at which very few axons are already myelinated (Figure 7).
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Figure 7: Electron micrograph of corpus callosum from 16 day-old
buprenorphine-treated female rat. At this stage of development in the corticospinal
tract, the majority of axons are unmyelinated, and there are very few axons that exhibit
myelin. Some of these myelinated axons are labeled with an asterisk (*).
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Based on our previous findings, we first investigated if pups exposed to a therapeutic
dose of buprenorphine exhibited at this earlier age any discernible alterations in the
diameter of axons in function of the number of myelin wraps.

As shown in Figure 8, for both controls and buprenorphine-exposed animals at 16 days
of age, there is a gradual increase in axonal diameter with an increased number of
wraps. For both males (Figure 8a) and females (Figure 8b), axons with one wrap of
myelin exhibit significantly larger diameters than those axons which are unmyelinated (p
< 0.0001). Moreover, axons with three wraps of membrane exhibited diameters that
were at least twice as large as unmyelinated axons. However, a comparison between
axons with equal number of wraps across the experimental groups did not indicate any
significant differences between controls and buprenorphine-treated animals at this age
of development.

Interestingly, when an “average axonal diameter” was calculated excluding those axons
that were unmyelinated or had only one wrap of myelin (Figure 9), buprenorphine
exposed females exhibited a modest but nevertheless significant increase in the caliber
of myelinated axons. In contrast, while the numerical average was also higher for the
treated males, the differences were not statistically significant.

These observations suggest that the greater buprenorphine effects previously observed
in the 26-day-old animals could result from a progressive drug effect that begins with
myelination but extends far beyond the initial steps of axo-glial interaction.
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Figure 8: Correlation between the number of wraps and axonal diameter in the
corpus callosum. As described under in “Materials and Methods”, the corpus callosum
of 16 day-old animals was analyzed by electron microscopy for axonal diameter and the
number of wraps. The graph depicts the results obtained by analysis of 65-200 axons
for each treatment group (control males, control females, buprenorphine-treated males,
buprenorphine-treated females). (a) males (b) females *p < 0.0001.
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Figure 9: Female pups exposed to buprenorphine exhibit a larger average axonal
diameter. Mid-sagittal sections of the corpus callosum from male and female 16 day-old
controls and buprenorphine-exposed animals were analyzed for axonal diameter as
described in “Materials and Methods”. The average diameter of axons with two or more
wraps was calculated for each treatment group. *p < 0.04.
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Since previous studies with 26-day old animals indicated that buprenorphine exposure
also resulted in a disproportionally thinner myelin sheath (Sanchez et al., 2008), we
attempted to determine g-ratios at 16 days of age to establish whether the same
buprenorphine effect was already observed at this earlier stage of development. As
described in the Materials and Methods section, to calculate the g-ratio, the diameter of
the axon was divided by the diameter of the axon with myelin sheath (Rushton 1951).
Only axons that exhibited compacted myelin were considered for this particular
analysis.

In contrast with the results obtained from the studies conducted in the older animals, a
comparison between buprenorphine-treated animals and controls at P16 shows no
significant difference in g-ratio for either sex (Figure 10). These new results suggest that
at this age, buprenorphine exposure may not yet affect the molecular mechanisms
underlying the determination of an optimal g-ratio.
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Figure 10: There is no significant difference in corpus callosum g-ratios between
controls and buprenorphine-treated animals at P16. As described in “Materials and
Methods”, axons with compacted myelin in the corpus callosum were analyzed, and gratios were calculated for each treatment group as diameter of naked axon/diameter of
axon with myelin.
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EXPOSURE TO BUPRENORPHINE RESULTS IN A LARGER PROPORTION OF
AXONS IN THE CORTICOSPINAL TRACT THAT EXHIBIT COMPACTED MYELIN

Previous research from our laboratory focused on the effects of buprenorphine in the
brain (Sanchez et al, 2008; Eschenroeder et al, Manuscript under review). We now
decided to extend these studies to the spinal cord, analyzing the corticospinal tract.
Myelination of this tract occurs before than in axons of the corpus callosum, beginning
at P10 (Gorgels et al., 1989, Gorgels et al., 1990). As shown in Figure 11, at P10,
oligodendrocytes in this tract contain abundant cytoplasm and cell processes highly
enriched in mitochondria, rough endoplasmic reticulum, and golgi apparatus, all
characteristics of actively myelinating cells.

The corticospinal tract was analyzed for degree of myelin compaction, such that any
axon that exhibited at least one wrap of myelin was placed into one of the following four
categories depicted in Figure 12: one wrap of myelin, “uncompacted” myelin, “partially
compacted” myelin, or compacted myelin. Placement of axons into each of these
categories was based on the following criteria:

(1) an axon surrounded by a single wrap of oligodendrocyte process was
characterized as having one wrap of myelin membrane,
(2) an axon surrounded by myelin membrane that appeared to be less than 40%
compacted was described as having “uncompacted” myelin,
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(3) an axon with myelin membrane that appeared to be between 40-60%
compacted was termed as having “partially compacted” myelin, and
(4) an axon exhibiting myelin with more than 60% compaction was categorized
as an axon with compacted myelin (Figure 12).

We analyzed the relative distribution of axons within each of these categories by
counting the total number of axons that exhibited at least one wrap of myelin, and then
expressed the results for each group as a percentage of this total.
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Figure 11: Electron micrograph of the corticospinal tract in a buprenorphinetreated 16 day-old female rat pup. Notice the presence of an oligodendrocyte
engaged in active myelination. This cell is characterized by the presence of abundant
cytoplasm and multiple mitochondria-enriched cell processes that are interacting with
and wrapping several axons (labeled with *) with myelin membranes at different stages
of compaction.
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Figure 12: The categories describing the degree of myelin compaction of axons in
the 16 day-old rat corticospinal tract. The top row depicts an entire axon while the
bottom row illustrates the interface of the axonal and glial membranes. (a) an axon
surrounded by a single wrap of oligodendrocyte process was characterized as having
one wrap of myelin membrane, (b) an axon surrounded by myelin membrane that
appeared to be less than 40% compacted was described as having “uncompacted”
myelin, (c) an axon with myelin membrane that appeared to be between 40-60%
compacted was termed as having “partially compacted” myelin, and (d) an axon
exhibiting myelin with more than 60% compaction was categorized as an axon with
compacted myelin.
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As depicted in Figure 13, we found that there is a greater proportion of axons
surrounded by compacted myelin in animals exposed to buprenorphine. Analysis within
each experimental group indicated that for control animals, there is a similar proportion
of both axons with "partially compacted" and compacted myelin. However, the
proportion of axons with "uncompacted" myelin was significantly larger than either of the
other two categories. Interestingly, this is in sharp contrast with the results for the
animals exposed to buprenorphine. In these pups the percentage of axons with
"partially compacted" myelin was, like the controls, about 25 %. However, at difference
with the controls, the number of axons with compacted myelin in the drug-exposed
animals reaches the proportion of those with "uncompacted" membrane and moreover,
significantly surpasses that of axons with “partially compacted” myelin (p < 0.002).

Since compact myelin may also be considered as a sign of more mature
oligodendrocytes, these results are consistent with previous findings from our laboratory
that suggest that exposure to a therapeutic dose of buprenorphine accelerates the
differentiation of oligodendrocytes (Sanchez et al., 2008, Eschenroeder et al.,
Manuscript under review).

As shown in Figures 14 and 15, the findings described above are also similarly detected
when the proportion of axons at different stages of myelination is separately analyzed in
from the male pups or female pups. Each sex also showed that buprenorphine-exposed
animals have a larger proportion of axons with compacted myelin as compared to
controls. Nevertheless, males and females exhibited some minor differences. Unlike the

56

buprenorphine-treated males (Figure 14), analysis of the buprenorphine-treated females
(Figure 14) showed that the proportion of axons with compacted myelin, although
numerically higher, is not significantly greater than the proportion of axons that exhibit
“partially compacted” myelin. It is important to note that the data for each treatment
group was based on four 17x17 micron images with 72-107 axons analyzed in each
(total of 280-374 axons per treatment group). Thus, the greater statistical significance of
the larger number of data for the combined sexes than for each sex alone suggests that
such difference between the sexes may diminish with a larger sample size.
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Figure 13: Buprenorphine exposure results in a larger proportion of axons with
compacted myelin in the corticospinal tract. Electron micrographs of the 16 day-old
corticospinal tract were analyzed for the degree of myelin compaction. The relative
proportions of each category was determined for buprenorphine-treated animals and
controls. *p < 0.002, **p < 0.0001.
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Figure 14: Buprenorphine exposure results in a larger proportion of axons with
compacted myelin in the male corticospinal tract. As described previously in
“Materials and Methods”, the corticospinal tract of 16 day-old male rat pups were
analyzed for degree of myelin compaction, and the relative proportions of each category
were calculated. *p < 0.007, **p < 0.003, ***p < 0.0006.
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Figure 15: Buprenorphine exposure results in a larger proportion of axons with
compacted myelin in the female corticospinal tract. Axons in the female
corticospinal tract were studied, and those exhibiting at least one wrap of myelin were
placed into one of the following categories: one wrap of myelin, “uncompacted” myelin,
“partially compacted” myelin, or compacted myelin. The relative proportions of each
were computed and graphed. *p < 0.02, **p < 0.009.

62

**

50

NS

NS

**

*

40

NS

30

1st Wrap
"Uncompacted"
"Partly Compacted"
Compacted

20
10
0

Control

Buprenorphine

Controls

Buprenorphine-Exposed

“Uncompacted” vs.
“Partially Compacted”

p < 0.009

“Uncompacted” vs.
“Partially Compacted”

p < 0.02

“Uncompacted” vs.
Compacted

p < 0.009

“Uncompacted” vs.
Compacted

NS

“Partially Compacted” vs.
Compacted

NS

“Partially Compacted” vs. NS
Compacted

63

The differences between the buprenorphine-treated males and females and their
respective controls is perhaps better observed in Figure 16. This comparison more
clearly demonstrates that animals exposed to buprenorphine have a greater proportion
of axons with compacted myelin.

As shown in Figure 16, controls and buprenorphine-treated animals exhibit no
difference in the proportion of axons with either a single myelin membrane wrap or
“partially compacted” myelin. However, animals exposed to buprenorphine exhibited a
significantly lower percentage of axons with “uncompacted” myelin, mirrored by a
similarly significantly higher percentage of axons with compacted myelin. The increase
in the proportion of axons exhibiting compacted myelin supports the previously
observed effects of buprenorphine exposure on oligodendrocyte maturation.

Results from analysis of only the male pups showed that exposure to buprenorphine
caused a decrease in the proportion of axons with “uncompacted” myelin and an
increase in the proportion of axons with compacted myelin (Figure 17a). Although
analysis of female pups also yielded a lower proportion of axons with “uncompacted”
myelin in buprenorphine-treated animals, Figure 17b shows that there was no difference
in the proportion of axons with compacted myelin (p = 0.19). Relative to each sex
individually, the combined data from the female and male animals demonstrated more
significant differences between control and buprenorphine-treated groups. This supports
the idea that a greater sample size could perhaps yield more significant results.
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Figure 16: Buprenorphine exposure results in a lower proportion of axons with
“uncompacted” myelin and a larger proportion of axons with compacted myelin.
Samples of the corticospinal tract were prepared as described in “Materials and
Methods” and analyzed for degree of myelin compaction as described earlier in
“Results”. Control animals and animals exposed to the drug were compared. *p < 0.006,
**p < 0.0009.
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Figure 17: Buprenorphine-treated 16 day-old rats exhibit a greater proportion of
axons with compacted myelin. Axons in the corticospinal tract of 16 day-old rat pups
were analyzed by electron microscopy and characterized according to the four stages of
myelination described earlier in this section (See Figure 12). The relative proportions
were of each were compared between controls and buprenorphine-treated animals. (a)
males. *p < 0.02. (b) females. **p < 0.04.
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DISCUSSION

Buprenorphine has long been considered a successful substitution therapy for opioid
addiction, but its use in pregnant addicts is still under speculation. Although methadone
is already an FDA-approved treatment for this condition, the associated increased risk
of neonatal abstinence syndrome (NAS) begs the pursuit of research into alternative
therapies (Finnegan, 1992). Buprenorphine is an attractive solution because, in addition
to its efficacy in non-pregnant addicts, it has been found to decrease the severity of
NAS (Jones et al., 2010). In general, however, there is limited knowledge of the in utero
effects of this drug. Exposure to other opioids has been shown to cause developmental
delay, altered fine motor skills, and attention deficit (Rosen and Johnson, 1982, Marcus
et al., 1984). Thus, it is important to thoroughly understand the potential effects of
buprenorphine on the development of the CNS before it can be established as a firstline treatment for pregnant opioid addicts.

Previous studies from our laboratory have indicated that perinatal exposure to
buprenorphine affects axonal diameter, myelination, and oligodendrocyte maturation in
the developing rat brain (Sanchez et al., 2008, Eschenroeder et al., Manuscript under
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review). The corpus callosum of 26 day-old animals that were perinatally exposed to
buprenorphine exhibited larger caliber axons and disproportionately thinner myelin
sheaths. This was accompanied by changes in MBP expression, suggesting that the
drug alters the timing of oligodendrocyte differentiation (Sanchez et al., 2008).

The present studies investigated the relationship between the extent of myelination and
axonal diameter, and potential actions of buprenorphine at postnatal day 16, an age that
immediately precedes the peak of rapid myelination in the corpus callosum. This
allowed us to assess the effects of buprenorphine at the early stages of axo-glial
interaction and subsequent myelination.

As described in the “Results” section, as axons are surrounded with additional myelin
lamellae, there is an increase in axonal diameter in both controls and buprenorphinetreated animals. Also true for both experimental groups is that axons with just one wrap
of myelin membrane already have a significantly larger diameter than unmyelinated
axons, and those axons with three or more wraps of myelin membrane exhibit axonal
diameters that are at least twice the size of their unmyelinated counterparts.
Interestingly, analysis of the average diameter of axons with at least two wraps of
myelin indicates that at this earlier age, buprenorphine-treated females already exhibit a
higher average axonal diameter than control animals. Although the absolute numerical
average was also higher for the buprenorphine-exposed males as well, it was not
statistically significant. In spite of the differences in axonal diameter, analysis of g-ratios
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shows no significant differences between controls and buprenorphine-treated animals,
suggesting that drug effects on myelin thickness occur later in the myelination process.

There are several lines of evidence indicating that larger caliber axons exhibit thicker
myelin sheaths in the nervous systems of many different animal species (Friede and
Samorajski, 1967, Friede and Samorajski, 1968, Hildebrand and Hahn, 1978). These
early studies examined the relationship between axonal diameter and either myelin
thickness or the number of myelin lamellae. The present results demonstrating an
increase in axonal diameter with an increased number of myelin wraps is consistent
with these previous findings. Additionally, there is evidence to support the idea that
compact myelin is required for radial growth (Brady et al., 1999). Since axons that
exhibit more wraps of myelin are more likely to exhibit compact myelin (Seggie and
Berry, 1972), it is possible that a more profound presence of compact myelin in larger
caliber axons may also be influencing radial growth in axons of the corpus callosum.

However, previous papers have also demonstrated the importance of the initial axo-glial
interactions as a determinant of axonal diameter (Hildebrand et al., 1985, Windebank et
al., 1985, Colello et al., 1994, Hsieh et al., 1994, Sanchez et al., 1996). It has been
shown that shiverer mutant mice, whose oligodendrocytes have the ability to wrap
axons but do not form myelin, still exhibit axons with normal caliber. This study was of
particular importance because it demonstrated that it was the early axo-glial interaction
and not necessarily the presence of compact myelin that regulated axonal caliber
(Sanchez et al., 1996). Based on this literature, for both controls and buprenorphine-
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exposed pups, the observed larger caliber of axons with one wrap of myelin membrane
versus those axons that were unmyelinated could be due to initial contact from an
oligodendrocyte.

Although there is much evidence to support the idea that axo-glial interactions are
occurring and affecting radial growth of axons, the mechanism of communication is still
not fully understood. The myelin glycoprotein MAG was originally investigated as a
potential molecule involved in axo-glial communication due to its location within the
layer of myelin directly overlying the axon (Trapp and Quarles, 1984). MAG has since
been implicated in bidirectional axo-glial signaling resulting from the initial contact of
myelinating cells and axons, triggering active myelination and the regulation of axonal
caliber (Yin et al., 1998, Quarles, 2007). As defined by its classification as a
glycoprotein, MAG is heavily glycosylated, and changes in its glycosylation have been
associated with early stages of myelination (Bartoszewicz et al., 1995). Additionally,
MAG has been shown to interact with the Src-family tyrosine kinase Fyn early in the
myelination process, by means of phosphorylation sites within its cytoplasmic domain,
resulting in downstream signaling cascades in the oligodendrocyte (Jaramillo et al.,
1994, Umemori et al., 1994, Fujita et al., 1998).

In this regard, it is important to point out that previous studies from our laboratory
showed that the brain of 12 day-old rat pups that were perinatally exposed to
therapeutic levels of buprenorphine exhibited elevated levels of MAG glycosylation.
Moreover, co-immunoprecipitation studies at this early age indicated increased
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interaction of MAG with Fyn (Sanchez et al, 2008). Notably, comparison with the control
group indicated that MAG protein levels in buprenorphine-exposed animals were also
elevated throughout the peak of myelination at 19 day postnatal and even at the end of
rapid myelin formation at around one month of age.

Thus, it is possible that the increase in average axonal diameter observed in the present
studies in buprenorphine-treated females could be due to altered MAG glycosylation
and association of MAG with Fyn early in the myelination process. Since this change in
MAG glycosylation is not seen in 19 day-old animals, it can be speculated that
buprenorphine affects axonal caliber via the alteration of mechanisms involving MAG at
the beginning of myelination, and perhaps these effects gradually taper off before they
reach the peak of rapid myelination. It is yet to be determined whether there are
buprenorphine-induced changes in MAG expression, glycosylation, and association with
Fyn at 16 days of age, and studies investigating this would have to be conducted to
verify or disprove this hypothesis.

Despite the existence of compelling evidence indicating that axo-glial interactions are a
major determinant of axonal caliber, accompanied by the previous and present results
suggesting that buprenorphine may indeed influence these events, the cascade of
molecular mechanisms leading to increased axonal diameter are not fully understood.
As described above, it is thought that these changes are mediated by MAG, and it is
also known that there are intrinsic elements within the neuron that affect axonal caliber
(Elder et al., 2001). More specifically, the axonal cytoskeleton is thought to play an
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important role in regulating axonal caliber in both the CNS and the PNS (Friede and
Samorajski, 1970, de Waegh et al., 1992, Sanchez et al., 1996, Sanchez et al., 2000).

Early studies showed that the number and density of NFs in axons affects axonal
caliber, such that either a larger accumulation of NFs or greater NF spacing results in
radial growth (Friede and Samorajski, 1970, de Waegh et al., 1992). The NFM and NFH
subunits possess multiple phosphorylation sites on sidearms extending from the cterminal regions. It is thought that when phosphorylated, repulsion between the negative
charges increases NF spacing, resulting in larger axonal diameter (Hirokawa et al.,
1984, Nakagawa et al., 1995).

This phosphorylation-dependent mechanism assumes the existence of NF kinasephosphatase systems subjected to regulation by extrinsic factors (de Waegh et al.,
1992, Sanchez et al., 2000). One of these factors could be MAG, as this glycoprotein
has been implicated in axo-glial interactions, and MAG-deficient mice exhibit a reduction
in axon caliber, NF spacing, and NF phosphorylation (Yin et al., 1998). Moreover,
experiments in which MAG-expressing COS cells were co-cultured with dorsal root
ganglion neurons demonstrated a direct role of this glycoprotein in regulating not only
NF levels and phosphorylation but also the expression and activity of extracellularsignal regulated kinases (ERK 1/2) and cyclin-dependent kinase-5 (cdk5), which have
been implemented in cytoskeletal protein phosphorylation (Dashiell et al., 2002).

74

Several lines of evidence, however, indicate that signaling between axons and glial
cells, however, is not unidirectional. It has long been thought that there is a minimum
axonal caliber that is necessary for myelination (Duncan 1934). Nevertheless, a direct
causative correlation between axonal caliber and the resulting myelin sheath is not clear
and furthermore, different mechanisms may underlie the final myelin thickness achieved
for axons within the PNS and CNS. Support for this possibility stems from studies
conducted on mouse mutants characterized by reduced axonal calibers resulting from a
deficiency of NFs. In these animals, axons of the PNS exhibited disproportionally and
abnormally thick myelin. In the spinal cord, however, the thickness of the myelin sheath
was proportional to the small caliber of the axons. These results suggested that in the
oligodendrocytes and Schwann cells respond to different cues and while axonal caliber
is a determinant factor for myelin thickness in the CNS, this is not the case in the PNS
where Schwann cells may read other intrinsic signals controlling myelin formation (Elder
et al., 2001).

It is important to consider these data when discussing the g-ratio, which is a numerical
value that describes the well-documented positive relationship between axonal caliber
and myelin thickness. The g-ratio, which represents optimal axonal myelination, is
highly conserved (Chomiak and Hu, 2009). There is a functional advantage to
possessing a larger axonal caliber and thicker myelin, because both of these factors
increase signal conduction velocity. However, nerve fiber growth is limited by the
amount of space in the nervous system, and thus the g-ratio represents a compromise
between optimal function and spatial constraints (Chomiak and Hu, 2009). For the PNS,

75

the optimal g-ratio is 0.6, while for the CNS, this value is 0.77 (Rushton 1951, Chomiak
and Hu, 2009).

Previous studies from our laboratory demonstrated elevated g-ratios in the corpus
callosum of 26 day-old animals perinatally exposed to buprenorphine (Sanchez et al.,
2008). However, we did not detect any significant g-ratio differences in the 16 day-old
animals. This could be due to the difficulties encountered in attempting to calculate gratios at this earlier age. In support of this possibility, several lines of evidence have
indicated that the correlation between axonal diameter and myelin thickness is less
obvious in immature axons (Friede and Samorajski 1967, Friede and Samorajski, 1968,
Fraher, 1972). Moreover, at this younger age, very few axons exhibited compact myelin,
which is a requirement for determining g-ratio.

However, it is equally possible to speculate that at this age, buprenorphine has not yet
affected the mechanisms underlying the determination of g-ratio. Since these
mechanisms are poorly understood, it is difficult to postulate exactly how buprenorphine
could be exerting its effects. Yet, axonal diameter has been shown to affect myelin
thickness (Elder et al., 2001). Thus, the earlier postulation that buprenorphine may be
directly affecting cytoskeletal elements, and not indirectly through MAG, becomes more
plausible. Alternatively, buprenorphine may be affecting some unidentified growth factor
or signaling molecule that is expressed within the axon as the caliber increases,
disrupting the mechanisms that consequently influence myelin thickness.
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As described above, radial growth of axons in the mammalian nervous system is an
apparently extremely complicated process, and although we know that axo-glial
interactions, MAG, and cystoskeletal elements are involved, it is certainly not this
simple. For instance, sulfatides, which are galactolipids particularly abundant in myelin,
have been shown to also affect axonal caliber (Marcus et al., 2006). Additionally,
compact myelin is supposedly required for radial growth of axons (Brady et al., 1999),
but the mechanisms are widely unknown. The process is further complicated by the
existence of bi-directional signaling between axons and glia, such that it is difficult to
decipher whether observed changes in animal models are the result of effects on glia,
axons, or a combination of both. Given the limitations in our current understanding of
these mechanisms, investigation into how buprenorphine affects such mechanisms
proves to be difficult, but may at the same time, shed light on this interesting problem.

The corpus callosum, however, represents just one area of the central nervous system
that was analyzed in these studies to assess the effects of buprenorphine on
myelination and axonal morphology. At 16 days of age, the corticospinal tract, which
carries motor information from the cerebral cortex to the body, is also in the early stages
of myelination (Gorgels et al., 1989).

The present results obtained from analysis of the 16 day-old rat corticospinal tract
indicate that perinatal exposure to buprenorphine does not alter the proportion of axons
that exhibit either just one wrap or “partially compacted” myelin. However, we found that
in the buprenorphine-treated animals, there is a lower proportion of axons that exhibit
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“uncompacted” myelin. Remarkably, this was accompanied by a complementary higher
proportion of axons that are ensheathed by already compacted myelin.

We hypothesize that the buprenorphine-induced changes in compaction could be due to
changes in oligodendrocyte differentiation, as increased compact myelin may be a sign
of more mature oligodendrocytes (Readhead et al., 1987). In support of this possibility,
previous studies from our laboratory have demonstrated that perinatal exposure of
animals to a therapeutic dose of buprenorphine results in early expression and
increased brain levels of MBP, a sign of accelerated oligodendrocyte maturation
(Sanchez et al., 2008). Furthermore, direct treatment of cultured oligodendrocytes with
low buprenorphine concentrations does not only result in elevated MBP levels but also
in augmented formation of membrane extensions and increased complexity of the cell
processes, all characteristics of more mature oligodendrocytes. Additional experiments
showed that, at least in culture, these stimulatory effects of buprenorphine reflected a
novel role of the μ-opioid receptor as a positive modulator of oligodendrocyte
development (Eschenroeder et al, Manuscript under review). This is in contrast to
previous studies which only suggested a role for this receptor at earlier stages of cell
development, functioning as a stimulator of proliferation in both neonatal
oligodendrocyte progenitors (Knapp and Hauser, 1996) and adult neuroprogenitors
(Persson et al., 2003). However, regardless of the effect, the precise mechanisms
downstream of μ-opioid receptor activation are still poorly understood.
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In this regard, unpublished recent observations from our laboratory showed that doses
of buprenorphine that stimulate oligodendrocyte development also elicit in these cells an
early transient increase in the phosphorylation of CREB (cyclic AMP response element
binding protein). CREB, a member of the leucine zipper family of transcription factors, is
activated by phosphorylation and subsequently binds to the consensus sequence
known as CRE (Ca2+/cyclic AMP-response element). Interestingly, it has been found
that several neurotransmitters and signal transduction pathways stimulate CREB
phosphorylation at different stages of oligodendrocyte development (Pende et al., 1997,
Sato-Bigbee et al., 1999). In immature oligodendrocyte progenitors, for instance, CREB
plays a crucial role in the stimulation of cell proliferation (Johnson et al., 2000) and
survival (Saini et al., 2004, Saini et al., 2005) induced by neurotrophin-3 (NT-3), directly
regulating the expression of the anti-apoptotic gene Bcl-2 (Saini et al., 2004).
Interestingly, at a later developmental stage when the cells are pre-oligodendrocytes,
CREB was found to be involved in regulating MBP expression in response to elevated
cyclic AMP (Sato-Bigbee and DeVries, 1996, Afshari et al., 2001). These findings
suggest that CREB is a mediator of multiple signals that modulate the extent of
oligodendrocyte development and myelination. Nevertheless, it remains to be
determined whether buprenorphine-mediated activation of the μ-opioid receptor and its
effect on CREB phosphorylation may be part of the signaling cascade underlying the
effects of this drug on axonal growth and myelination observed in the present studies.

It is important to stress that while this thesis investigated the perinatal effects of
therapeutic doses of buprenorphine, supra-therapeutic drug levels may have very
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different effects and also work through distinct mechanisms. As described before, recent
studies from our laboratory have demonstrated that animals exposed to a therapeutic
dose of buprenorphine exhibited elevated MBP expression (Sanchez et al., 2008,
Eschenroeder et al., Manuscript under review), increased complexity of oligodendrocyte
morphology, and a greater proportion of pre-oligodendrocytes that could become
mature oligodendrocytes (Eschenroeder et al., Manuscript under review). These
findings suggested that low doses of buprenorphine accelerate oligodendrocyte
differentiation. Conversely, supra-therapeutic doses of buprenorphine induce opposite
effects, namely decreased MBP expression (Sanchez et al., 2008, Eschenroeder et al.,
manuscript under review), simpler oligodendrocyte morphology, and fewer preoligodendrocytes that could mature into oligodendrocytes (Eschenroeder et al.,
manuscript under review). These findings indicated that higher doses of buprenorphine
delay oligodendrocyte development.

Further studies indicated that the bell-shaped dose-dependent effect of buprenorphine
on oligodendrocyte differentiation could be attributed to the involvement of different
opioid receptors. As discussed above, the stimulatory actions on oligodendrocyte
maturation exerted by low dose buprenorphine involve the μ-opioid receptor. At high
doses, however, the results indicated that buprenorphine also works through the
nociceptin/orphanin FQ receptor (NOP), a G protein-coupled receptor known to be
involved in pain regulation but never before implicated in the regulation of
oligodendrocyte development (Eschenroeder et al., Manuscript under review).
Importantly, those studies showed that buprenorphine effects mediated by the NOP
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receptor were able to counteract the positive actions on cell development mediated by
the μ-opioid receptor. Thus, buprenorphine dose-dependent effects uncovered novel
and opposing roles of the μ-opioid- and NOP receptors in CNS development. The
results suggested that balance between signaling mediated by μ-opioid receptor
activation and a novel, yet unidentified pathway that includes the NOP receptor, plays a
crucial role in the timing of oligodendrocyte maturation and myelin synthesis
(Eschenroeder et al, 2011). It is important to point out that the above mechanisms of
buprenorphine signaling were mainly based on the effects if this drug on cultured
oligodendrocytes.

Oligodendrocyte differentiation, however, is not the only factor that determines the onset
of myelination. Studies of the optic nerve have demonstrated that while oligodendrocyte
differentiation occurs in the rostro-caudal direction, myelination proceeds in the opposite
direction. Results from these studies suggested that axonal diameter was acting as an
additional signal to determine the initiation of myelination (Colello et al., 1995). As
discussed previously, there is well-established bi-directional signaling between axons
and oligodendrocytes that could be influenced by buprenorphine, causing accelerated
myelination in exposed animals.

It is possible to hypothesize that accelerated oligodendrocyte maturation induced by
therapeutic doses of buprenorphine may result in increased myelin compaction by a
mechanism dependent on MAG. As already indicated, previous results from our
laboratory have demonstrated that perinatal exposure to therapeutic buprenorphine
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doses causes an early increase in MAG glycosylation and interaction with Fyn (Sanchez
et al., 2008). Besides the already established role of MAG in initiating axo-glial
interactions, several lines of evidence have suggested that this molecule also plays a
role in myelin stability. Studies conducted in MAG-null mice have shown that these
animals exhibit structural abnormalities in the periaxonal region, such as reduced
oligodendroglial cytoplasm in the inner myelin sheath, and separation of this sheath
from the axon (Li et al., 1994, Montag et al., 1994, Ma et al., 2003). In aging mutant
mice, axons exhibited a decreased caliber, reduced NF spacing, and an increased
incidence of degeneration (Pan et al., 2005). However, the mechanisms underlying
MAG effects on myelin compaction or stability are not clear. Recent studies have
investigated the role of gangliosides, a family of glycosphingolipids that contain sialic
acid and are expressed on the neuronal plasma membrane (Schnaar, 2007). It is
thought that gangliosides, such as GD1a and GT1b, are receptors for MAG (Yang et al.,
1996, Vyas and Schnaar, 2001). Studies with B4galnt1 mutant mice, which are
incapable of synthesizing these complex gangliosides, exhibit axonal degeneration,
decreased NF spacing, and decreased axonal caliber (Sheikh et al., 1999, Chiavegatto
et al., 2000). Interestingly, this resembles the morphology of MAG-null mice, suggesting
that interaction of MAG with GD1a or GT1b could be part of the mechanism that
influences both myelin stability and axonal caliber. Based on these findings, it can be
speculated that the buprenorphine-induced elevation in MAG glycosylation and
interaction with Fyn could be facilitating myelin stability, thus increasing the proportions
of axons in the spinal cord exhibiting compacted myelin.
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It is also very likely that increased proportion of axons with compacted myelin observed
in the buprenorphine-exposed animals is a direct result of the accelerated and
augmented expression of MBP (Sanchez et al., 2008, Eschenroeder et al., Manuscript
under review). As described above, MBP has been implicated in initiating (Privat et al.,
1979, Readhead et al., 1987) and also maintaining myelin compaction (Matthieu et al.,
1986). Because low buprenorphine doses appear to accelerate oligodendrocyte
development, it is also reasonable to hypothesize that in addition to MAG and MBP,
other myelin components important for myelin formation and compaction may also be
increased. Among these could be PLP and galactocerebrosides. Besides being a major
myelin component, several lines of evidence have demonstrated that PLP affects myelin
stability, since knockout animals exhibit an abnormal intraperiod line (Duncan et al.,
1987, Klugmann et al., 1997). Glactocerebroside (GalC) and its sulfated derivative,
sulfatide, which are major lipid components of myelin, also have a well-established role
in myelin stability (Coetzee et al., 1996, Coetzee et al., 1998, Dupree et al., 1998,
Marcus et al., 2002, Marcus et al., 2006). Thus, it would be important to determine
whether buprenorphine may induce a general increase in the expression of all myelin
components or on the other hand, have specific effects on selective molecules which
like MAG and MBP are crucial to myelin compaction.

Certainly, analysis of myelin compaction in the spinal cord has yielded very significant
differences between buprenorphine-treated animals and controls. However, it is
important to acknowledge the possibility that fixation artefacts could account for some
axons to be characterized as exhibiting “uncompacted” or “partially compacted” myelin.
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It is possible that to a certain extent, some of these axons may actually exhibit
compacted myelin, but significant portions of the myelin lamellae were separated during
the fixation procedure, giving the appearance of myelin that had not yet been
compacted. It remains controversial whether there is a biological reason for this, one
may hypothesize that such artefacts could occur because immature myelin may be still
"loosely" compacted and therefore more susceptible to disarray during fixation.

Overall, investigations into actions of this drug prove to be difficult, particularly because
some of the observed effects may be due to its active metabolite, norbuprenorphine
(Robinson, 2002a). Additionally, our limited understanding of normal radial growth and
myelination in the CNS further complicate the issue, and we acknowledge the possibility
that other unknown mechanisms may also play a role in mediating the effects of
buprenorphine. Effects on myelination in vivo may also likely involve indirect effects
mediated by buprenorphine actions on other CNS cells such as astrocytes or microglia,
which may potentially modulate myelination. One may also speculate that there are
direct effects on neurons, as suggested by previous studies from Dr. Susan Robinsonʼs
laboratory, which indicate that there are buprenorphine-induced delays in neuronal
development in the striatum (Robinson, 2002b).

Ironically, although the biological complexity of the system apparently hinders our
investigations, these pharmacological studies will eventually provide us with insight into
normal developmental processes. In summary, the present studies provide further
evidence on the potential effects of buprenorphine on myelination in the maturing brain
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and now extend these actions to the spinal cord. Together with our previous findings,
these observations stress the importance of opioid signaling during CNS development.
Ultimately, it is our hope that the information gained from these studies will help to
design safer treatment protocols for pregnant opioid addicts, minimizing deleterious
effects in both mothers and babies. Additionally, these studies may also shed light unto
mechanisms that play a role in demyelinating diseases, such as multiple sclerosis in the
CNS or Charcot-Marie-Tooth disease in the PNS.
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